Wedbush Has Optimistic Outlook of Chimerix FY2025 Earnings

Chimerix, Inc. (NASDAQ:CMRX) – Analysts at Wedbush upped their FY2025 earnings per share estimates for shares of Chimerix in a research report issued on Tuesday, February 18th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will earn ($0.03) per share for the year, up from their previous forecast of ($1.09). Wedbush has a “Outperform” rating and a $7.00 price objective on the stock. The consensus estimate for Chimerix’s current full-year earnings is ($0.99) per share. Wedbush also issued estimates for Chimerix’s Q4 2025 earnings at $0.74 EPS, FY2026 earnings at ($0.89) EPS and FY2027 earnings at $0.02 EPS.

Separately, HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Chimerix in a report on Tuesday.

Chimerix Stock Performance

CMRX stock opened at $5.08 on Thursday. The company’s 50 day moving average price is $3.68 and its 200 day moving average price is $1.90. The firm has a market capitalization of $456.90 million, a price-to-earnings ratio of -5.40 and a beta of 0.35. Chimerix has a fifty-two week low of $0.75 and a fifty-two week high of $5.53.

Insider Transactions at Chimerix

In other news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the sale, the chief executive officer now owns 609,603 shares in the company, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last ninety days, insiders sold 20,760 shares of company stock valued at $91,175. 13.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Chimerix

Several hedge funds and other institutional investors have recently bought and sold shares of CMRX. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Chimerix by 66.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock worth $321,000 after purchasing an additional 138,098 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Chimerix by 154.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock valued at $2,846,000 after purchasing an additional 496,823 shares during the period. Stoneridge Investment Partners LLC grew its stake in Chimerix by 22.5% during the 4th quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 8,134 shares during the last quarter. Peapod Lane Capital LLC acquired a new position in Chimerix during the fourth quarter worth approximately $2,626,000. Finally, Valeo Financial Advisors LLC increased its position in Chimerix by 78.8% during the fourth quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company’s stock worth $509,000 after buying an additional 64,420 shares during the period. 45.42% of the stock is currently owned by institutional investors and hedge funds.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.